Barzilai University Medical Center

69 Research Day 2020 Barzilai University Medical Center 48 IS NEUTROPHIL-TO-LYMPHOCYTE RATIO A PREDICTION MARKER FOR SUCCESS OF IMMUNOTHERAPY? PRELIMINARY RESULTS Noam Asna 1 , Ron Batash 2 , Asaf Sigron 1 , Tatiana Harkovski 1 , Moshe Schaffer 1 ,3 1 Department of Oncology, Barzilai University Medical Center, Ashkelon, Israel. 2 Department of Orthopedics, Barzilai University Medical Center, Ashkelon, Israel. 3 Faculty of Medicine, Ben Gurion University of the Negev, Beer Sheva, Israel. Background Cancer immunotherapy treatments enhance the cancer treatment approach. The neutrophil-to- lymphocyteratio (NLR) has been associated with cancer prognosis, affecting progression, chemosensitivity, radiosensitivity and toxicity. Hypothesis NLR ratio in patients with squamous cell carcinoma, adenocarcinoma of the lungs, soft tissue sarcoma, renal cell carcinoma can be assessed and correlated to the clinical response by RECIST criteria using computerized tomography (CT) scans. Objectives Describe the capabilities of NLR ratio as a prediction marker for success of immunotherapy. Results In regression analysis, older patients were found to respond better to immunotherapy treatment than younger patients. NLR was 4.26 ± 2.25 (p < 0.01) in the older patients group and 2.84 ± 0.90 (p < 0.01) in the younger patients group. No difference in response according to tumor type (p = 0.479) was observed. Conclusions We provide preliminary evidence demonstrating that low NLR helps in understanding the value of the underlying immune system in expecting a good outcome to immune treatment. The NLR is a simple and available biomarker, easy to apply in clinical practice.